1
项与 Mesenchymal Stem Cell Therapy(Cairo University) 相关的临床试验Allogenic Mesenchymal Stem Cells in Hemophilia: a Pilot Study
Hemophilia is caused by a single-gene defect resulting in familial bleeding disorder. Small increase in gene products could transform a severe form of hemophilia into a mild one. Stem cells from extrahepatic sources are being considered for clinical applications in liver cell therapy as they possess high in vitro culture potential and could be used in transplant procedures. We studied the differentiation of bone marrow hematopoietic stem cells (BM-HSCs) from hemophilia patients' relatives into factor 8 (FVIII)-producing hepatocyte-like cells aiming to expand patients' donor options for partial replacement of mutant liver cells by healthy cells in hemophilia A patients which could manage the severity of the bleeding disorder.
BM-HSCs from hemophilic families will be cultured in short-liquid hepatic induction medium. Appearance of hepatic phenotype will be evaluated by alpha-fetoprotein expression using immunocytochemistry. Functional evaluation of transdifferentiation will be done through detection of albumin synthesis using microalbumin assay kit, factor VIII activity by one-stage clotting assay and expression of FVIII messenger RNA( mRNA) by reverse transcription ( RT-PCR).
Inducing the differentiation of BM-HSCs by in-vitro manipulation may become a valuable tool to provide a cell source for hepatocyte transplant procedures for treatment of hemophilia patients.
100 项与 Mesenchymal Stem Cell Therapy(Cairo University) 相关的临床结果
100 项与 Mesenchymal Stem Cell Therapy(Cairo University) 相关的转化医学
100 项与 Mesenchymal Stem Cell Therapy(Cairo University) 相关的专利(医药)
100 项与 Mesenchymal Stem Cell Therapy(Cairo University) 相关的药物交易